Top Page
SRx Health Solutions
(SRXH)
SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)
SRx Health Solutions Business Overview & Revenue Model
SRx Health Solutions Earnings Call Summary
SRx Health Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -8.78M | 9.11M | 34.98M | 118.94M | 92.63M | 46.01M |
| Gross Profit | -1.12M | 2.08M | 12.86M | 23.61M | 13.31M | 13.70M |
| EBITDA | 5.50M | -11.00M | 438.00K | -7.05M | -539.40K | 8.30M |
| Net Income | -32.58M | -63.00M | -168.00K | -11.14M | -2.45M | 2.98M |
Balance Sheet | ||||||
| Total Assets | 8.40M | 11.72M | 15.80M | 64.51M | 34.79M | 77.42M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 1.83M | 3.07M | 2.07M | 1.66M | 28.94M |
| Total Debt | 4.47M | 6.24M | 45.31M | 39.38M | 17.85M | 10.33M |
| Total Liabilities | 8.00M | 11.15M | 7.15M | 70.80M | 33.86M | 19.55M |
| Stockholders Equity | 407.00K | 567.65K | -55.12M | -6.29M | 927.48K | 57.88M |
Cash Flow | ||||||
| Free Cash Flow | -9.32M | -11.00M | -4.40M | 1.58M | 3.13M | -12.21M |
| Operating Cash Flow | -9.31M | -11.00M | -4.36M | 2.85M | 3.38M | -11.86M |
| Investing Cash Flow | 5.13M | 8.24M | -2.25M | -19.78M | -6.83M | -353.00K |
| Financing Cash Flow | 8.10M | 16.98M | 5.22M | 16.43M | 3.80M | 37.16M |
SRx Health Solutions Technical Analysis
SRx Health Solutions Risk Analysis
SRx Health Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $7.83B | 14.54 | 6.93% | 1.56% | 9.45% | 167.00% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
53 Neutral | $2.26B | 4.52 | 71.62% | 4.80% | -1.69% | -61.89% | |
45 Neutral | $91.58M | -3.11 | ― | ― | ― | ― | |
41 Neutral | $13.24M | 0.07 | ― | ― | -8.12% | ― |
SRx Health Solutions Corporate Events
On January 6, 2026, SRx Health Solutions, Inc., listed on the NYSE American under the symbol SRXH, received notice that the exchange had accepted its plan to regain compliance with continued listing standards related to minimum stockholders’ equity. The exchange had previously notified the company on October 14, 2025, that it was out of compliance after reporting negative stockholders’ equity of $45.9 million as of June 30, 2025 and losses in three of its four most recent fiscal years ended December 31, 2024. With the NYSE American’s acceptance of its remediation plan, SRx Health Solutions’ listing will continue under an extension through July 14, 2026, during which the company must execute its plan to restore equity levels, provide quarterly progress updates to the exchange, and seek to regain full compliance, a move that stabilizes its immediate listing status but underscores ongoing financial pressures and execution risk for shareholders and other stakeholders.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.19 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On December 17, 2025, stockholders of SRx Health Solutions, Inc. holding 45.42% of the company’s voting power approved by written consent a series of transformative corporate actions as of the December 12, 2025 record date, including a proposed name and ticker change to EMJX, Inc. and “EMJX” on the NYSE American, contingent on closing a transaction to acquire EMJ Crypto Technologies Inc., CCC Crypto Corp., and all associated AI-based intellectual property assets. Shareholders also authorized the potential issuance of 20% or more of the company’s outstanding common stock, possibly below market value, to fund the crypto and AI-focused acquisition and approved the appointment of Eric M. Jackson, PhD as chief executive officer and board chairman in connection with the deal, signaling a strategic pivot toward AI-driven crypto trading technologies. In addition, investors approved an increase in shares available under the 2019 Incentive Award Plan to 10% of outstanding shares (with a minimum threshold), elected four directors to serve until the 2026 annual meeting, endorsed executive compensation on an advisory basis, and ratified Davidson and Company LLP as the independent auditor for 2025, with all measures passing without opposition and an information statement to be filed with the SEC before the transaction is consummated.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On December 16, 2025, SRx Health Solutions, Inc. announced a definitive agreement to acquire EMJ Crypto Technologies Inc. and CCC Crypto Corp. for approximately $55 million in an all-stock transaction. This strategic move aims to establish a next-generation digital asset treasury operating system, leveraging EMJX’s platform that uses quantitative models and AI for multi-asset digital treasury management. The transaction, subject to customary closing conditions and shareholder approval, is expected to close in the first quarter of 2026. Upon completion, Eric M. Jackson, founder and CEO of EMJX, will lead the combined company as CEO and Chairman, marking a significant shift towards disciplined risk management and capital allocation in digital asset treasuries.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On November 19, 2025, SRx Health Solutions, Inc. filed a Certificate of Amendment to its Certificate of Incorporation, following approval from stockholders on October 8, 2025. This amendment significantly increases the number of authorized shares of the company’s common stock from 200 million to 5 billion, while the number of authorized preferred shares remains unchanged at 4 million. The amendment’s implementation potentially enhances the company’s capital structure, offering greater flexibility for future financing and growth opportunities.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
SRx Health Solutions, Inc., a company listed on the NYSE American under the ticker SRXH, announced on November 10, 2025, the appointment of Sammy Dorf to its Board of Directors. Sammy Dorf, known for his leadership in the cannabis and capital markets, brings a wealth of experience from his previous roles, including Executive Chairman of Flora Growth Corp. and Co-Founder of Verano Holdings. His expertise in strategic development and growth initiatives is expected to enhance SRx Health Solutions’ market positioning and operational strategies.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
SRx Health Solutions, Inc. entered into a Securities Purchase Agreement on October 27, 2025, with accredited investors to issue Series A convertible preferred stock and accompanying warrants. On October 31, 2025, the company completed a private placement, selling 19,035 shares of Series A Preferred Stock and 54,527,811 warrants for approximately $15.23 million. This move is part of a broader strategy to strengthen its financial position, with implications for increased flexibility in its capital structure and potential impacts on shareholder value.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On October 14, 2025, SRx Health Solutions, Inc. received a notice from NYSE American LLC indicating non-compliance with the listing standards due to insufficient stockholders’ equity, as required by Section 1003(a)(ii) of the NYSE American Company Guide. The notice does not immediately affect the company’s stock trading, but SRx Health must submit a compliance plan by November 13, 2025, to avoid potential delisting. The company is actively working on regaining compliance by July 14, 2026, and the notice does not impact its business operations or SEC reporting requirements.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.